To The Moon

Novo Nordisk Q3: A Third Guidance Raise This Year, But Can It Protect Pricing? A Put Seller's Deep Dive, With the Strike Zone and the Trigger

Written Wednesday 4 Nov, SGT, a few hours after Novo's 7:30 AM CET release. The US session hasn't opened yet.

THE HEADLINE: A THIRD RAISE

Novo's 2026 outlook has improved three times:

- May: adjusted sales and operating profit expected to fall 4% to 12% at constant exchange rates

- August: raised to a decline of 0% to 6%

- Today: raised again to between -2% and +2%

Management says the driver is "increased expectations for GLP-1 product sales". A year that looked like a steep decline now looks roughly flat. That's the real story.

THE QUARTER (DKK)

- Net sales: 79.2 billion, up 6% in kroner and 4% at constant exchange rates

- Adjusted operating profit: 31.7 billion, up 27% at constant exchange rates

- Reported operating profit: 23.0 billion, down 9% at constant exchange rates

Read both profit lines. The adjusted number looks strong partly because Q3 2025 carried 9 billion kroner of restructuring costs, which makes the comparison easy. The reported number is down because this quarter took 8.7 billion kroner of non-cash impairments: 4.6 billion on ziltivekimab and 4.1 billion to shrink the manufacturing network.

Where the growth came from:

- Wegovy pill: 5.39 billion kroner, against roughly 4.6 billion analysts expected. It has now launched in eight markets, including the US, UK, Germany and UAE.

- Wegovy holds more than 50% of new US patient starts in branded obesity drugs.

- Ozempic pill: since its US launch in May, weekly new prescriptions are about double the pre-launch level under the old Rybelsus brand.

- Both US and International Operations grew.

Pipeline:

- CagriSema showed 21% weight loss at week 68 in REDEFINE 9.

- In diabetes (REIMAGINE 5), CagriSema produced 12.4% weight loss against 9.1% for tirzepatide 5 mg at week 60. The US launch is targeted for early 2027, subject to approval.

CAN NOVO PROTECT PRICING?

Honestly, no one in this class can right now. The clearest data comes from Lilly's Q3 last week:

- Revenue: $24.4 billion, up 39%

- Company-wide: volume up 53%, realized price down 15%

- US: volume up 41%, price down 7%

- Mounjaro: $10.7 billion. Zepbound: $5.4 billion.

- 2026 guidance raised to $91 to $92 billion

So the GLP-1 class is trading price for volume, and the market leader is cutting price faster than anyone. Novo's sales growth of only 4% at constant exchange rates, while it launches pills in eight markets, tells you the same thing.

The pill war matters here. Novo's Wegovy pill brought in 5.39 billion kroner this quarter. Lilly's Foundayo pill made $184 million, below the $234 million analysts expected. Novo is clearly ahead in oral GLP-1s for now. Morningstar notes Lilly's pill may be easier to manufacture and roll out internationally, so that lead isn't guaranteed.

WHAT BEST SHOWS DEMAND HASN'T PEAKED?

The topic asks: volumes, net price, or capacity? My answer is volumes, specifically new patient starts and new prescriptions.

- Net price is falling across the whole class, at both Lilly and Novo. Falling prices don't mean demand has peaked. They mean companies are choosing volume and access.

- Capacity has stopped being the constraint. Novo just took a 4.1 billion kroner charge to shrink its manufacturing network. A company that can't make enough doesn't close plants.

- Volume is the clean signal. More than 50% of US branded new starts, and Ozempic pill prescriptions doubling, tell you more about demand than any price number.

HOW A PUT SELLER READS IT

The stock: closed Tuesday at $40.19 and was trading around $41.43 (+3.09%) on Tiger after the release. Options had priced in a move of about 6.9% for the report.

Gate 1, 200-day SMA: FAIL.

The 200-day average is about $43.55. Even after today's bounce, NVO is about 5% below it, and the 100-day ($44.15) is also overhead. My hard rule is no puts below the 200-day. A good report doesn't override that.

Gate 2, earnings calendar: PASS.

The report is out today. The next one should be in early February, so December expiries are clean.

Gate 3, volatility: RECHECK.

Before the report, 30-day IV was about 41% against historical volatility of about 21%, nearly a 2:1 ratio. After a report, IV usually drops sharply. I'll recheck IV Rank of at least 40%, IV Percentile of at least 45% and IV at least 1.2 times historical volatility on the live chain.

THE STRIKE ZONE, IF THE GATE TURNS GREEN

Expiry: Dec 18 monthly, 43 days out.

Volatility used: 30% to 35%, my estimate of post-report IV.

My two-anchor method:

- The moving average anchor is 43.55 x 0.98 = about $42.68. It's above the current price, so it can't be used yet. That's the 200-day gate showing up in the numbers.

- The one standard deviation floor is about $36.5 to $37.2.

- At those levels, the delta is only about 0.10 to 0.12, below my 0.15 minimum, so I move up into the 0.15 to 0.25 band.

Result: a $37 to $38 strike for Dec 18.

- $37 put: delta about 0.12 to 0.15, model premium about $0.25 to $0.41

- $38 put: delta about 0.18 to 0.21, model premium about $0.42 to $0.61

That's only about 0.7% to 1.6% on cash over 43 days. The premium is thin because Novo isn't a volatile stock once the report is out. These are Black-Scholes estimates, not quotes.

Size: one $38 put ties up $3,800. At my 2% cap for a non-core name, that fits an account of about $190,000. This is one of the few quality names where a smaller account can stay inside the rules.

Exits, set on day one: 50% take-profit GTC, a stop at 2.5x premium, one roll at most.

MY VERDICT

Novo had a good quarter: a third raise, a pill launch that beat estimates, and a lead in oral GLP-1s. But a put seller doesn't get paid for a good quarter. They get paid for selling insurance at the right price, above a structure that holds. Right now Novo is below its 200-day, and once IV drops the premium will be thin. My trigger is a close back above $43.55. When that happens and the volatility gates pass, I'll look at the Dec 18 $37 to $38 zone. Until then, a cheap stock isn't the same thing as a safe put.

Your turn: what's the better demand signal for GLP-1s: Novo's 50%-plus share of new US starts, or Lilly's 53% volume growth? And would you rather sell puts on Novo below its 200-day or wait for the reclaim?

This is my personal trading framework, shared for education. It is not investment advice. Options carry significant risk, including assignment and losses larger than the premium collected. Premiums are model estimates, not quotes. Always verify live chain data before trading.

$NVO $LLY